Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03777215 · ClinicalTrials.gov registry record · Early Phase 1

Angiotensin-(1-7) and Energy Expenditure in Human Obesity

A Early Phase 1 study of Obesity, sponsored by Amy Arnold.

Active
Registry status
Early Phase 1
Development phase
30
Enrollment target
1
Study location

NCT03777215: Active Early Phase 1 study of Obesity, sponsored by Amy Arnold.

NCT03777215 is a Early Phase 1 study of Obesity that is active but no longer recruiting, run by Amy Arnold. The registered enrollment target is 30 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT03777215, a Early Phase 1 study of Obesity, is active but no longer recruiting, sponsored by Amy Arnold.

ACTIVE NOT RECRUITING
Registry status
Early Phase 1
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

The objective of this study is to better define the role of the hormone angiotensin-(1-7) in energy balance. We will test the overall hypothesis that angiotensin-(1-7) increases resting energy expenditure and promotes markers of heat production (thermogenesis) in white adipose tissue in human obesity.

Primary Outcome

Change in resting energy expenditure measured by indirect calorimetry at baseline and at end of angiotensin-(1-7) versus saline infusion.

Conditions Studied

Obesity

Interventions

  • DRUG Saline
  • DRUG Angiotensin-(1-7)

Study Locations (1)

Pennsylvania

  • Penn State Milton S. Hershey Medical Center - Hershey

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2019-09-26
Est. Completion 2026-12
Phase Early Phase 1
Amy Arnold

2 total trials

What the registry record for NCT03777215 still lists

NCT03777215 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (96% lower).

The record links to 1 condition, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Saline is the first listed.

NCT03777215 reports a single indexed study location in Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT03777215 about?

NCT03777215 is a clinical study titled "Angiotensin-(1-7) and Energy Expenditure in Human Obesity". The objective of this study is to better define the role of the hormone angiotensin-(1-7) in energy balance. We will test the overall hypothesis that angiotensin-(1-7) increases resting energy expenditure and promotes markers of heat production (thermogenesis) in white adipose tissue in human obesit...

What is the current status of trial NCT03777215?

This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 30 participants. The study started on 2019-09-26. Estimated completion is 2026-12.

What conditions does trial NCT03777215 study?

This clinical trial studies the following conditions: Obesity.

What interventions are being tested in trial NCT03777215?

The interventions under investigation include: Saline (DRUG), Angiotensin-(1-7) (DRUG).

Who is sponsoring clinical trial NCT03777215?

This trial is sponsored by Amy Arnold, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03777215 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Obesity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03777215's enrollment target sits among peer trials

30 851st of 1053 higher than 173 of 1,053 other Obesity trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT03777215, the US trial registry maintained by the National Library of Medicine. NCT03777215 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.